ArticleDermatologic therapy2022

Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma.

Rony Shreberk-Hassidim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.